Celltrion began to work on type-2 diabetes treatment. After securing DPP-4 inhibitor Nesina (alogliptin) through the acquisition of Takeda Pharmaceutical’s Asia Pacific assets, Celltrion is likely to release a combination drug, too, industry officials said.On Tuesday, the Ministry of Food and Drug S
Samsung Biologics said it would purchase a land site to construct its fifth and sixth plants in Songdo, Incheon.In a public filing on Tuesday, the company said it planned to buy “Songdo International City High-tech Industrial Cluster (C)) (430 Songdo-dong, Yeonsu-gu, Incheon)” from the Incheon Free
TiumBio said it would release study results showing that its investigational immunotherapy has superior immune activation than MedPacto’s vactosertib.MedPacto brushed off TiumBio’s announcement, calling it “meaningless,” but the company seemed upset about it at the same time.TiumBio disclosed the ab
Prestige Biopharma is drawing attention from market watchers after announcing that its biosimilar HD201 has demonstrated equivalence in efficacy and safety profiles compared with the reference product Herceptin.Prestige Biopharma said Thursday that it reported the final results of its phase 3 clinic
Celltrion Healthcare said it has succeeded in winning a bid for Remsima (ingredient: infliximab), a biosimilar for AbbVie's autoimmune disease treatment Humira, in Brazil, the largest pharmaceutical market in Latin America.Under the contract, Celltrion Healthcare will deliver Remsima to Brazil's fed
ABL Bio, a Korean biotech company, said it received 75 million (about 91 billion won) upfront payment from Sanofi as part of the licensing agreement for ABL301, an antibody targeting alpha-synuclein and IGF1R to treat degenerative brain diseases, including Parkinson's disease.In January, ABL Bio sig
Kolon TissueGene, which avoided delisting with a one-year grace period last year, is still facing the risk of delisting because of its financial instability.The Korea Exchange (KRX) said on Monday that it added one more reason to designate Kolon TissueGene as an administrative issue because the comp
TiumBio, a Korean biotech firm, is speeding up clinical trials of TU2218, investigational immunotherapy, in the U.S. and Korea.In the U.S., the Kosdaq-listed company is testing TU2218 in a phase 1a study. The company enrolled the first patient in January. The patient enrollment and drug administrati
Medipost said that it started administering SMUP-IA-01, an injection type knee osteoarthritis treatment, in a phase 2 trial in Korea.The phase 2 trial follows a previous phase 1 clinical trial of SMUP-IA-01, where the company confirmed the safety and improvement of pain and joint function in 12 pati
Abion had said it completed patient enrollment for a phase 1 clinical trial of anticancer medicine. However, the ClinicalTrials.gov site recently showed that the study was still “recruiting” patients.According to the site, operated by the U.S. National Institutes of Health, Abion changed the status
CKD Bio said Thursday it signed a contract manufacturing organization (CMO) deal with EnhancedBio to produce ionizable lipids, a key substance in EN-LNP technology.EN-LNP is a lipid nanoparticle (LNP) platform to deliver gene therapy materials, including vaccines and treatments to cells. The technol
CHA Biotech released the topline results of the phase 1 clinical trial of CBT101, a natural killer (NK) cell therapy to treat solid cancer, on Thursday.CBT101 is experimental immunotherapy made by multiplying the patient’s NK cells that play a significant role in congenital immunity.CHA Biotech said
The Russian invasion of Ukraine might disrupt ongoing drug trials conducted by Korean biotech companies in Ukraine, industry watchers worried.However, Korean companies said their clinical trials in Ukraine were part of multinational ones, and the ongoing conflict would rarely affect global studies.C
GC said it has applied for product approval for Maralixibat, an Alagille syndrome (ALGS) treatment, to the Food and Drug Safety Ministry.ALGS is a rare genetic disease in children in which the hepatic biliary tract decreases and bile stagnates, and the only available treatment is currently liver tra
Seegene, a multiplex molecular diagnostics company, said Thursday that it has developed a diagnostic reagent that can identify the Covid-19 infection in 30 minutes.Seegene’s new product, Allplex SARS-CoV-2 fast MDx Assay, has obtained the Conformity European In-Vitro Diagnostics (CE-IVD) marking. Th
The International Vaccine Institute (IVI) said the Ministry of Health and Welfare had been named it to operate “2022 Global Bio-Intensive Training Courses,” a Korean government program.IVI will provide workforce training in vaccine and biologics R&D and manufacturing for people from low- and middle-
Biotech companies developing an mRNA-based Covid-19 vaccine are busy responding to the Omicron variant.They are conducting clinical trials of existing candidate vaccines and simultaneously studying their efficacy against virus variants.According to the Ministry of Food and Drug Safety’s data release
Aptamer Sciences said on Friday that it signed a CDMO (contract development and manufacturing organization) agreement with China’s Asymchem for developing an anticancer drug.The deal involves GMP process development and production of clinical samples of AST-201, an aptamer-drug conjugate (ApDC)-base
NeoImmuneTech said it released preclinical results of NT-I7 in mouse models of glioblastoma (GBM) in Clinical Cancer Research, a major oncology journal published by the American Association for Cancer Research (AACR).NeoImmuneTech is developing NT-I7 as a T cell amplifier immunotherapy.The preclinic
The Korea Exchange said it tentatively decided to delist Sillajen from the tech-heavy Kosdaq market. Following the KRX decision, the Kosdaq market committee will determine whether to delist the biotech firm.On Tuesday, the KRX held a meeting of the corporate review committee and said it would kick S